

References

- American Cancer Society: What is prostate cancer. American Cancer Society: Information and resources for cancer: breast, colon, prostate, lung and other forms, web. 15 June 2010.
- American Cancer Society: prostate cancer. Cancer information database 2013.
- Abate-shen, C. and Shen, M. M. 2000. Molecular genetics of prostate cancer. *GenesDev*, 14, 2410-34.
- Albert, R. H. and Clark, M. M. 2008. Cancer screening in the older patient. *Am Fam Physician*, 78, 1369-74.
- Andriole, G., Bruchovsky, N., Chung, L. W., Matsumoto, A. M., Rittmaster, R., Roehrborn, C., Russell, D. and Tindall, D. 2004. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. *JUrol*, 172, 1399-403.
- Aumuller, G. and Adler, G. 1979. Experimental studies of apocrine secretion in the dorsal prostate epithelium of the rat. *Celltissueres*, 198, 145-58.
- Ayala, A. G. and Ro, J. Y. 2007. Prostatic intraepithelial neoplasia: recent advances. *Arch pathol lab med*, 131, 1257-66.
- Bernards, R. and Weinberg, R. A. 2002. A progression puzzle. *Nature*, 418, 823.
- Bonekamp, D., Jacobs, M. A., El-khouli, R., Stoianovici, D. and Macura, K. J. 2011. Advancements in MR imaging of the prostate: from diagnosis to interventions. *Radiographics*, 31, 677-703.

- Bostwick, D. G. 1996. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. *Cancer*, 78, 330-6.
- Bostwick, D. G., Burke, H. B., Djakiew, D., Euling, S., Ho, S. M., Landolph, J., Morrison, H., Sonawane, B., Shifflett, T., Waters, D. J. and Timms, B. 2004. Human prostate cancer risk factors. *Cancer*, 101, 2371-490.
- Bushman, W. 2009. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. *UrolClinNorthAm*, 36, 403-15, v.
- Carvalho, G. F., Smith, D. S., Mager, D. E., Ramos, C. and Catalona, W. J. 1999. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. *JUrol*, 161, 835-9.
- Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L. and et al. 1994. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. *JUrol*, 151, 1283-90
- Chao, Y, H, Stephens, J, Raymond, O, Tania, R, Hein and F 2009. Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. *AsianJournalofAndrology*, 11, 131-37.

- Dalley, A. F. 1999. The American Association of Clinical Anatomists (AACA): the other American anatomy association. *AnatRec*, 257, 154-6.
- Denmeade, S. R. and Isaacs, J. T. 1997. Prostate cancer: where are we and where are we going *BrJUrol*, 79 Suppl 1, 2-7.
- Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A. and Chinnaiyan, A. M. 2001. Delineation of prognostic biomarkers in prostate cancer. *Nature*, 412, 822-6.
- Djuibegovic, M., Beyth, R. J., Neuberger, M. M., Stoffs, T. L., Vieweg, J., Djuibegovic, B. and Dahm, P. 2010. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. *BMJ*, 341, c4543.
- Epstein, J. I. 2010. An update of the Gleason grading system. *JUrol*, 183, 433-40.
- Fair, W. R., Fleshner, N. E. and Heston, W. 1997. Cancer of the prostate: a nutritional disease *Urology*, 50, 840-8.
- Fitzpatrick, P., Corcoran, N. and Fitzpatrick, J. M. 1998. Prostate cancer: how aware is the public *BrJUrol*, 82, 43-8.
- Gallagher, R. P. and Fleshner, N. 1998. Prostate cancer: 3. Individual risk factors. *CMAJ*, 159, 807-13.
- Gleason, D. F. 1992. Histologic grading of prostate cancer: a perspective. *HumPathol*, 23, 273-9.
- Hoffman, R. M., Gilliland, F. D., Eley, J. W., Harlan, L. C., Stephenson, R. A., Stanford, J. L., Albertson, P. C., Hamilton, A. S., Hunt, W. C. and Potosky, A. L. 2001. Racial and ethnic

- differences in advanced-stage prostate cancer: the prostate cancer outcomes study. *JNatlCancerInst*, 93, 388-95.
- Homma, Y., Kawabe, K., Tsukamoto, T., Yamaguchi, O., Okda, K., Aso, Y., Watanabe, H., Okajima, E., Kumazawa, J., Yamaguchi, T. and Ohashi, Y. 1996. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. *IntJUrol*, 3, 261-6.
- Klezovitch, O., Chevillet, J., Mirosevich, J., Roberts, R. L., Matusik, R. J. and Vasioukhin, V. 2004. Hepsin promotes prostate cancer progression and metastasis. *CancerCell*, 6, 185-95.
- Leav, I., Plescia, J., Goel, H. L., Li, J., Jiang, Z., Cohen, R. J., Languino, L. R. and Altieri, D. C. 2010. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. *AmJPathol*, 176, 393-401.
- Leytus, S. P., Loeb, K. R., Hagen, F. S., Kurachi, K. and Davie, E. W. 1988. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. *Biochemistry*, 27, 1067-74.
- Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A. and Hemminki, K. 2000. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *NEnglJMed*, 343, 78-85.
- Magee, J. A., Araki, T., Patil, S., Ehrig, T., True, L., Humphrey, P. A., Catalona, W. J., Watson, M. A. and Milbrandt, J. 2001.

- Expression profiling reveals hepsin overexpression in prostate cancer. *CancerRes*, 61, 5692-6.
- McNeal, J. E. 1988. Normal histology of the prostate. *Am J Surg Pathol*, 12, 619-33.
- Moran, P., Li, W., Fan, B., Vij, R., Eigenbrot, C. and Kirchhofer, D. 2006. Pro-urokinase-type plasminogen activator is a substrate for hepsin. *JBiolChem*, 281, 30439-46.
- Natarajan, S., Marks, L. S., Margolis, D. J., Huang, J., Macairan, M. L., Lieu, P. and Fenster, A. 2011. Clinical application of a 3D ultrasound-guided prostate biopsy system. *UrolOncol*, 29, 334-42.
- Optenberg, S. A., Clark, J. Y., Brawer, M. K., Thompson, I. M., Stein, C. R. and Friedrichs, P. 1997. Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. *Urology*, 50, 665-72.
- Pal, P., Xi, H., Kaushal, R., Sun, G., Jin, C. H., Jin, L., Suarez, B. K., Catalona, W. J. and Deka, R. 2006. Variants in the hepsin gene are associated with prostate cancer in men of European origin. *HumGenet*, 120, 187-92.
- Pearson, J. D., Luderer, A. A., Metter, E. J., Partin, A. W., Chan, D. W., Fozard, J. L. and Carter, H. B. 1996. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. *Urology*, 48, 4-9.
- Robinson, V. L., Kauffman, E. C., Sokoloff, M. H. and Rinker-Schaeffer, C. W. 2004. The basic biology of metastasis. *CancerTreatRes*, 118, 1-21.

- Roemer, A., Schwettmann, L., Jung, M., Stephen, C., Roigas, J., Kristiansen, G., Loening, S. A., Lichtinghagen, R. and Jung, K. 2004. The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markersJUrol, 172, 2162-6.
- Steinberg, G. D., Carter, B. S., Beaty, T. H., Childs, B. and Walsh, P. C. 1990. Family history and the risk of prostate cancer. Prostate, 17, 337-47.
- Stephen, C., Yousef, G. M., Scorilas, A., Jung, K., Jung, M., Kristiansen, G., Hauptmann, S., Kishi, T., Nakamura, T., Loening, S. A. and Diamandis, E. P. 2004. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. JUrol, 171, 187-91.
- Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., Mcadams, M., Timmerman, M. M., Brody, L. C. andTucker, M. A. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. NEnglJMed, 336, 1401-8.
- Tanimoto, H., Yan, Y., Clarke, J., Korourian, S., Shigemasa, K., Parmley, T. H., Parham, G. P. and O'brien, T. J. 1997. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. CancerRes, 57, 2884-7.
- Tozlu, S., Girault, I., Vacher, S., Vendrell, J., Andrieu, C., Spyrtos, F., Cohen, P., Lidereau, R. and Bieche, I. 2006. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-

- time reverse transcription-PCR approach.
EndocrRelatCancer, 13, 1109-20.
- Tsuji, A., Torres-Rosado, A., Arai, T., Le Beau, M. M., Lemons, R. S., Cuou, S. H. and Kurachi, K. 1991. Hepsin, a cell membrane-associated protease. Characterization, tissue distribution, and gene localization. *JBiolChem*, 266, 16948-53.
- Tsukise, A. and Yamada, K. 1984. Complex carbohydrates in the secretory epithelium of the goat prostate. *HistochemJ*, 16, 311-9.
- Wasserman, N. F. 2006. Benign prostatic hyperplasia: a review and ultrasound classification. *RadiolClinNorthAm*, 44, 689-710, viii.
- Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang-Rodriguez, J., Moskaluk, C. A., Frierson, H. F., Jr. and Hampton, G. M. 2001. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. *CancerRes*, 61, 5974-8.
- Wu, Q. and Parry, G. 2007. Hepsin and prostate cancer. *FrontBiosci*, 12, 5052-9.
- Yao, V., Berkman, C. E., Choi, J. K., O'keefe, D. S. and Bacich, D. J. 2010. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. *Prostate*, 70, 305-16.